Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Salvage Treatment with Ofatumumab and ESHAP (O-ESHAP) for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma After First-Line Chemotherapy: Interim Analysis of a Phase II Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Carmen Martinez, MD, Mercedes Rodriguez-Calvillo, María José Terol, MD, PhD, Blanca Xicoy, MD, PhD, Ramón García-Sanz, Elena Perez-Ceballos, Alberto Cantalapiedra, Eva Domingo-Domènech, MD, Miguel Hernández, Antonia Sampol, MD, Manuel Espeso, Javier Briones, MD, Javier Lopez, Anna Sureda, MD

Blood (2012) 120 (21): 1630.

https://doi.org/10.1182/blood.V120.21.1630.1630

Published: 2012

Journal Articles

Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial

Francisco Javier Peñalver, José Antonio Márquez, Soledad Durán, Pilar Giraldo, Carlos Montalban, María José Ramírez, Juan Manuel Sancho, María José Terol, MD, PhD, Francisco Javier Capote, Antonio Gutiérrez, Blanca Sánchez, Miguel Canales, María Dolores Caballero

Blood (2012) 120 (21): 1639.

https://doi.org/10.1182/blood.V120.21.1639.1639

Published: 2012

Journal Articles

The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL)

Noridza Rivera-Rodriguez, MD, Fernando Cabanillas, MD, Carlos Montalban, Jose Francisco Tomas, MD, María José Terol, MD, PhD, Armando López-Guillermo, MD, Wandaly I. Pardo, MD, Orestes A. Pavia, MD, Margarita Bruno, MD, Karen Janice Santiago, Pablo Guisado-Vasco, MD, PhD, Angel Ruedas, MD, Raquel de Oña, Silvia Solorzano, Ana Isabel Teruel, MD, Laura Garcia-Sanchis, Jordina Rovira, MD, Ivan Dlouhy

Blood (2012) 120 (21): 1596.

https://doi.org/10.1182/blood.V120.21.1596.1596

Published: 2012

Journal Articles

Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy

Pau Abrisqueta, MD, Neus Villamor, MD, PhD, María José Terol, MD, PhD, Eva González-Barca, MD, PhD, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose Antonio García-Marco, MD, PhD, Yolanda González, MD, Felix Carbonell, MD, PhD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, MD, Ana Muntanola, MD, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD. PhD, Francesc Bosch, MD, PhD

Blood (2012) 120 (21): 3930.

https://doi.org/10.1182/blood.V120.21.3930.3930

Published: 2012

Journal Articles

Vascular Endothelial Growth Factor (VEGF) Increases B-CLL CELL Migration Through Regulation of CXCR4/SDF1 AXIS

Sandra Ballester, Pilar Eroles, PhD, Blanca Navarro, MD, PhD, Anabel Teruel, MD, Carlos Solano, MD, PhD, María José Terol, MD, PhD

Blood (2012) 120 (21): 3917.

https://doi.org/10.1182/blood.V120.21.3917.3917

Published: 2012

Journal Articles

Biological and Clinical Significance of CD81 Expression by Clonal Plasma Cells in High-Risk Smoldering and Symptomatic Multiple Myeloma (MM) Patients,

Blood (2011) 118 (21): 3936.

https://doi.org/10.1182/blood.V118.21.3936.3936

Published: 2011

Journal Articles

Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005<65years Trials: Clinical Value and Biological Insights,

Blood (2011) 118 (21): 3938.

https://doi.org/10.1182/blood.V118.21.3938.3938

Published: 2011

Journal Articles

High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Blood (2011) 118 (21): 630.

https://doi.org/10.1182/blood.V118.21.630.630

Published: 2011

Journal Articles

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)

Francesc Bosch, MD, PhD, Pau Abrisqueta, Neus Villamor, MD. PhD, María José Terol, MD, PhD, Eva González-Barca, MD, Marcos González, MD, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A. Garcia-Marco, MD, PhD, Yolanda Gonzalez, Felix Carbonell, MD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, Ana Muntanola, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD. PhD

Blood (2011) 118 (21): 293.

https://doi.org/10.1182/blood.V118.21.293.293

Published: 2011

Journal Articles

The FLIPI2 SCORE Predicts PROGRESSION-FREE SURVIVAL (PFS) and OVERALL SURVIVAL (OS) IN AN INDEPENDENT SERIES of Follicular LYMPHOMA: A Single Institution EXPERIENCE

María José Terol, MD, PhD, Ana Isabel Teruel, Paula Amat, Danella Elaluf, Mar Tormo, MD, PhD, Carlos Solano, MD, PhD

Blood (2010) 116 (21): 3128.

https://doi.org/10.1182/blood.V116.21.3128.3128

Published: 2010

NARROW

Salvage Treatment with Ofatumumab and ESHAP (O-ESHAP) for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma After First-Line Chemotherapy: Interim Analysis of a Phase II Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial

The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL)

Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy

Vascular Endothelial Growth Factor (VEGF) Increases B-CLL CELL Migration Through Regulation of CXCR4/SDF1 AXIS

Biological and Clinical Significance of CD81 Expression by Clonal Plasma Cells in High-Risk Smoldering and Symptomatic Multiple Myeloma (MM) Patients,

Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005<65years Trials: Clinical Value and Biological Insights,

High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)

The FLIPI2 SCORE Predicts PROGRESSION-FREE SURVIVAL (PFS) and OVERALL SURVIVAL (OS) IN AN INDEPENDENT SERIES of Follicular LYMPHOMA: A Single Institution EXPERIENCE

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only